<p class="바탕글" style="line-height: 140%; font-family: 굴림; font-size: 12pt; font-weight: bold; margin-bottom: 13px; -ms-layout-grid-mode: char;"><span style="font-family: 굴림; font-size: 12pt; font-weight: bold;">[제약</span><span style="font-family: 굴림; font-size: 12pt; font-weight: bold;">] 스코틀랜드 NHS, 6종의 신약 허가</span></p> <p class="바탕글" style="line-height: 140%; font-family: 굴림; font-size: 12pt; margin-bottom: 13px; -ms-layout-grid-mode: char;"><span style="font-family: 굴림; font-size: 12pt;">▪NHS 가격 정책부는 암, 만성 편두통, 고 콜레스테롤, 철 결핍증을 위한 6종의 신약을 재 허용</span></p> <p class="바탕글" style="line-height: 140%; font-family: 굴림; font-size: 12pt; margin-bottom: 13px; -ms-layout-grid-mode: char;"><span style="font-family: 굴림; font-size: 12pt;">▪비소세포성폐암 치료제 타그리소(Tagrisso), 위장 및 폐 신경내분비종양 치료제 아피니토(Afinitor), </span></p> <p class="바탕글" style="line-height: 140%; font-family: 굴림; font-size: 12pt; margin-bottom: 13px; -ms-layout-grid-mode: char;"><span style="font-family: 굴림; font-size: 12pt;">결장암 치료제 론서프(Lonsurf), 만성 편두통 치료제 보톡스(Botox), 고 콜레스테롤 치료제 레파타(Repatha), 철결핍 치료제 디아퍼(Diafer)가 재 허용</span></p> <p class="바탕글" style="line-height: 140%; font-family: 굴림; font-size: 12pt; margin-bottom: 13px; -ms-layout-grid-mode: char;"><span style="font-family: 굴림; font-size: 12pt;">▪반면 특발성 야간다뇨증 치료제 녹디마(Noqdima)는 사용 금지 처분</span></p> <p class="바탕글" style="line-height: 140%; font-family: 굴림; font-size: 12pt; margin-bottom: 13px; -ms-layout-grid-mode: char;"> </p> <p class="바탕글" style="line-height: 107%; font-family: 굴림; font-size: 12pt; margin-bottom: 21px; -ms-layout-grid-mode: char;"><span style="font-family: 굴림; font-size: 12pt;">[Pharma Times, 2017.02.14.]</span></p> <p class="바탕글" style="line-height: 107%; font-family: 굴림; font-size: 12pt; margin-bottom: 21px; -ms-layout-grid-mode: char;"><a href="http://www.pharmatimes.com/news/six_new_medicines_accepted_for_nhs_use_in_scotland_1186655">http://www.pharmatimes.com/news/six_new_medicines_accepted_for_nhs_use_in_scotland_1186655</a></p>
소스입니다. Ctrl+C를 눌러 클립보드로 복사하세요

닫기